Bioactive Components and Possible Activities of Medicinal Mushrooms in Alleviating the Pathogenesis of Nonalcoholic Fatty Liver Disease (Review).

Nonalcoholic fatty liver disease (NAFLD) is a global disease that is closely associated with obesity, type 2 diabetes mellitus, and cardiovascular disease. Excessive fat accumulation, fatty degeneration, and chronic inflammation of the liver activate the progression of NAFLD from simple steatosis to nonalcoholic steatohepatitis and further to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The underlying mechanism for the development and progression of NAFLD is complex and a multiple-hit hypothesis including dietary, environmental, genetic, and epigenetic factors has been raised. Increased de novo lipogenesis, decreased lipolysis, and insulin resistance are associated with the development of NAFLD. Currently, no effective drug therapies are approved for the treatment of NAFLD. Several medicinal mushrooms have been found to have significant weight control and gut microbe modulation activities and antihypertriglyceridemic, antihyperglycemic, antioxidant, and anti-inflammatory effects, which may be useful to prevent and attenuate the development and progression of NAFLD. These beneficial effects are associated with mushrooms' bioactive components, such as polysaccharides, dietary fibers, antioxidants, and other compounds derived from fruiting bodies, cultured mycelium, and/or broth of medicinal mushrooms. This article presents an overview of multiple aspects of NAFLD, including the epidemiology, pathogenesis, management, and treatment. The bioactive components and possible activities of medicinal mushrooms in alleviating the pathogenesis of NAFLD are also reviewed.